Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network.

Abstract

BACKGROUND:

The availability of direct oral anticoagulants (DOAC) in clinical practice has transformed the health care provided to patients for the prevention and treatment of thromboembolism. Safety and efficacy data guide clinicians in the choice of the drug used. To date, no evidence is available from head-to-head trials comparing different DOAC with regard to safety and efficacy; information is mainly derived from several meta-analyses and real-life studies. Conclusions from these studies are inconsistent and unsatisfactory. The evaluation of self-reported adverse drug reactions (ADR) available from databases of drug-regulatory agencies such as the Italian Medicines Agency (AIFA) pharmacovigilance database represents a novel aid to guide decision-making.

OBJECTIVE:

To analyze potential suspected ADR of DOAC using a previously described risk index (RI) in daily clinical practice in Italy.

METHODS:

The National Pharmacovigilance Network database (from the AIFA website) was searched in order to retrieve information on all ADR related to oral anticoagulants occurring from 2013 to 2018. The ADR RI for each drug was calculated, where an RI = 1 indicates a balance between the percentage of ADR share and the percentage of market share for each DOAC; and an RI <1 indicates a rate of ADR lower than the rate of market share (safer DOAC). The following DOAC molecules were considered: dabigatran, rivaroxaban, apixaban, and edoxaban.

RESULTS:

The results showed that rivaroxaban is the DOAC with the lowest RI among the 4 molecules available today in Italy.

CONCLUSIONS:

Based on the RI, we identified rivaroxaban as the DOAC having the best safety profile.

• Authors: Carlo Lavalle, Luca Di Lullo, Antonio Bellasi, Claudio Ronco, Stefano Radicchia, Vincenzo Barbera, Gioacchino Galardo, Agostino Piro, Michele Magnocavallo, Martina Straito, Massimo Uguccioni
• Journal: Cardiorenal medicine (Cardiorenal Med) Vol. 10 Issue 4 Pg. 266-276 ( 2020) ISSN: 1664-5502 [Electronic] Switzerland
• PMID: 32353846 (Publication Type: Journal Article, Review)
• Copyright: © 2020 S. Karger AG, Basel.

Chemical References

• Anticoagulants
• Rivaroxaban

Topics

• Anticoagulants (adverse effects)
• Drug-Related Side Effects and Adverse Reactions
• Humans
• Italy
• Pharmacovigilance
• Rivaroxaban